Jan. 28-29

Mountain View, CA

Receive PMWC updates & offers by email

First:
Last:
Email:

Luminary Committee

Brian Druker

Brian Druker, Co-inventor, Gleevec

Brian Druker, Co-inventor, Gleevec

Brian Druker M.D., Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, OHSU, and an Investigator of the Howard Hughes Medical Institute After having trained in oncology at Harvard's Dana-Farber Cancer Institute, Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. His work was instrumental in the development of Gleevec, a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard, and many others.

George Church

George Church, Co-developer, Human Genome Project

George Church, Co-developer, Human Genome Project

George Church, Ph.D. Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT With Walter Gilbert he developed the first direct genomic sequencing method in 1984 and helped initiate the Human Genome Project in 1984 while he was a Research Scientist at newly-formed Biogen Inc. He invented the broadly-applied concepts of molecular multiplexing and tags,homologous recombination methods,and DNA array synthesizers. Technology transfer of automated sequencing & software to Genome Therapeutics Corp. resulted in the first commercial genome sequence, (the human pathogen, Helicobacter pylori) in 1994. He initiated the Personal Genome Project (PGP) in 2005 and research on synthetic biology. He is director of the U.S. Department of Energy Center on Bioenergy at Harvard & MIT and director of the National Institutes of Health (NHGRI) Center of Excellence in Genomic Science at Harvard, MIT & Washington University. He has been advisor to 22 companies, most recently co-founding (with Joseph Jacobson, Jay Keasling, and Drew Endy) Codon Devices, a biotech startup dedicated to synthetic biology and (with Chris Somerville) founding LS9, which is focused on biofuels. He is a senior editor for Nature EMBO Molecular Systems Biology.

Kary Banks Mullis

Kary Banks Mullis, Nobel laureate & Inventor of PCR

Kary Banks Mullis, Nobel laureate & Inventor of PCR

He received a Bachelor of Science degree in chemistry from the Georgia Institute of Technology and a Ph.D. in biochemistry from the UC Berkeley, after which Dr. Mullis became a postdoctoral fellow in pediatric cardiology at the University of Kansas Medical School. In 1977, he began two years of postdoctoral work in pharmaceutical chemistry at the UCSF. Dr. Mullis then joined the Cetus Corporation, where, for seven years, he conducted research on oligonucleotide synthesis and invented the polymerase chain reaction. Dr. Mullis received a Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR), a method of amplifying DNA which multiplies a single, microscopic strand of the genetic material billions of times within hours. Among his many other awards, Dr. Mullis was also awarded the Japan Prize in 1993 for the PCR invention and was inducted into the Inventors Hall of Fame in 1998.

Philip R. Lee

Philip R. Lee, Former Director of Health Services, USAID

Philip R. Lee, Former Director of Health Services, USAID

Dr. Philip R. Lee is Senior Scholar, Philip R. Lee Institute for Health Policy Studies and Professor Emeritus of Social Medicine, Department of Medicine, School of Medicine at the University of California, San Francisco. He has been a member of the UCSF faculty since 1969. He retired in 1993 and resumed active Emeritus status in 1997. From July 1993 through January 1997, he served as Assistant Secretary for Health, U.S. Department of Health and Human Services. Before going to Washington, Dr. Lee served as Director of the Institute for Health Policy Studies, which he founded with Lewis Butler, JD at the University of California, San Francisco (UCSF) in 1972. He served as chancellor of UCSF from 1969 to 1972. Prior to joining the UCSF faculty he was Assistant Secretary for Health and Scientific Affairs in the Department of Health, Education and Welfare from 1965 to 1969, and was Director of Health Services in the Agency for International Development from 1963 to 1965. A native of San Francisco, Dr. Lee received his M.D. from Stanford in 1948 and an M.S. from the University of Minnesota in 1955. He is the author or co-author of 145 articles in the health field, and he has co-authored numerous books, including "Pills, Profits and Politics"; "Primary Care in a Specialized World"; "Exercise and Health"; "Pills and the Public Purse"; "Prescriptions for Death: the Drugging of the Third World"; "Drugs and the Elderly: Clinical, Social, and Policy Perspectives"; and "Bad Medicine". He has edited two books, one (The Nation's Health) is in its seventh edition. While at UCSF, his research and teaching endeavors in the field of health policy focused on physician payment, prescription drugs, reproductive health policy, health manpower and AIDS-related issues. His current research is focused on diversity in medical education, where the primary focus is a case study of Stanford and UCSF medical schools since 1960. He has just completed a study of Medicare and prescription drugs. Throughout his career he has served (officially and unofficially) as advisor and mentor for countless fellows and students who have gone on to important positions in government, academia and the private sector.

Program Committee

Alexis Borisy

Alexis Borisy, Partner, Third Rock Ventures

Alexis Borisy, Partner, Third Rock Ventures

Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science based organizations such as Foundation Medicine, Blueprint Medicines, and CombinatoRx. Alexis is a Partner at Third Rock Ventures, where he focuses on the formation, development and strategy of new companies. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the MIT Technology Review Innovator of the Year.

Brook Byers

Brook Byers, Investment Partner, Kleiner Perkins Caufield Byers

Brook Byers, Investment Partner, Kleiner Perkins Caufield Byers

Brook Byers has been a partner with Kleiner Perkins Caufield & Byers since 1977. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 110 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB's offices and went on to become public companies with an aggregate market value of more than US$8 billion. He serves on the board of directors of CardioDX, Crescendo, Five Prime Therapeutics, Foundation Medicine, OptiMedica, Pacific Biosciences, Inc., Tethys, Veracyte and XDx, Inc.

Bruce Quinn

Bruce Quinn, Senior Health Policy Specialist, Foley Hoag

Bruce Quinn, Senior Health Policy Specialist, Foley Hoag

Dr. Quinn practices within the firm's Government Strategies practice, where he focuses on Medicare coverage and payment matters for new technologies. Bruce is a national leader in the areas of Medicare coverage and payment, claims and billing, and Medicare contractor reform processes. He works with companies, providers and venture capital investors to develop strategies for Medicare payment for new technologies. A large part of this work is on local and national coverage decisions. Before serving in the Medicare Part B program, Bruce was a physician executive in the Health & Life Sciences division of Accenture and was a clinician-scientist at Northwestern University School of Medicine, leading pathology research for Northwestern's NIH-funded Alzheimer Research Center.

Cliff Reid

Cliff Reid, CEO, Complete Genomics

Cliff Reid, CEO, Complete Genomics

Clifford A. Reid, Ph.D., is our co-founder and has served as our President, Chief Executive Officer and Chairman since July 2005 and as a member of our board of directors since July 2005. From March 2003 to September 2005, Dr. Reid was Vice President of Collaborative Solutions at Open Text Corporation, a software company. In 1995, Dr. Reid co-founded Eloquent, Inc., a digital video communications company, and served as its Chief Executive Officer until 1999 and as its Chairman until 2003, when it was acquired by Open Text. In 1988, Dr. Reid co-founded Verity, Inc., an enterprise text search engine company, and served as its Vice President of Engineering from 1988 to 1992 and as its Executive Vice President from 1992 to 1993. Dr. Reid received a B.S. in Physics from the Massachusetts Institute of Technology, an M.B.A. from Harvard University and a Ph.D. in Management Science and Engineering from Stanford University.

Edward Abrahams

Edward Abrahams, President, PMC

Edward Abrahams, President, PMC

Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to over 200 today. Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University. Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior.

George Lundberg

George Lundberg, Editor in Chief, CollabRx

George Lundberg, Editor in Chief, CollabRx

In addition to serving as Editor-In-Chief for CollabRx, Dr. Lundberg is President and Chair of the Board of Directors of The Lundberg Institute, a Consulting Professor, Stanford University, and Editor at Large for MedPage Today from Everyday Health. Dr. Lundberg has had thirty years combined experience as Editor in Chief of JAMA (The Journal of the American Medical Association), 10 AMA specialty journals, AMA News, Medscape, The Medscape Journal and e-Medicine from Web MD. A 1995 "pioneer" of the medical internet, Dr. Lundberg was born in Florida, grew up in rural southern Alabama and holds earned and honorary degrees from North Park College, Baylor University, the University of Alabama (Birmingham and Tuscaloosa), the State University of New York, Syracuse, Thomas Jefferson University and the Medical College of Ohio. He completed a clinical internship in Hawaii and a pathology residency in San Antonio. He served in the US Army during the Vietnam War in San Francisco and El Paso, leaving as a lieutenant colonel after 11 years. Dr. Lundberg was then Professor of Pathology and Associate Director of Laboratories at the Los Angeles County/USC Medical Center for 10 years, and for five years was Professor and Chair of Pathology at the University of California, Davis. Dr. Lundberg has worked in tropical medicine in Central America and Forensic Medicine in New York, Sweden and England. His major professional interests are toxicology, violence, communication, physician behavior, patient safety, and health system reform. He is also a past President of the American Society of Clinical Pathologists. He is a frequent lecturer, radio and television guest, and a member of the Institute of Medicine of the National Academy of Sciences, In 2000, the Industry Standard dubbed Dr. Lundberg "Online Health Care's Medicine Man".

Hakan Sakul

Hakan Sakul, Sr. Director and Global Head of Diagnostics and Oncology, Pfizer

Hakan Sakul, Sr. Director and Global Head of Diagnostics and Oncology, Pfizer

Hakan serves as the Global Head of Diagnostics and Oncology Leads, leading Pfizer’s Diagnostics efforts across its pharmaceutical portfolio. He received his BS and MS degrees from Ankara University in Turkey. He completed his PhD degree in Quantitative Genetics from the University of Minnesota as the recipient of a “Freedom from Hunger” Scholarship from The Rotary Foundation in its inaugural year in 1986. Following a postdoctoral program at the University of California-Davis, Hakan worked in the biotech industry in human genetics, pharmacogenomics and statistical genetics. His entry into the pharmaceutical industry was through Parke-Davis Pharmaceuticals – Warner Lambert as Director of Human Genetics, Statistical Genetics and Pharmacogenetics programs. Following the merger of W-L and Pfizer, Hakan served as Site Head for Clinical Pharmacogenomics in Pfizer’s Connecticut site. Hakan assumed his current role in mid-2007. A member of the Editorial Board of the Personalized Medicine Journal, the Organizing Committee of the annual Personalized Medicine meeting at Harvard, and the author of over 30 scientific refereed articles and several book chapters, Hakan has served as an invited speaker on many panel discussions and scientific meetings. His external representation of Pfizer includes memberships on the Clinical Science and Technology Committee of The Personalized Medicine Coalition, the Research Tools and Molecular Diagnostics Sub Team of BIO, and the California Healthcare Institute Diagnostics Working Group. Hakan is keenly interested in applications of companion diagnostics, pharmacogenomics and related technologies to the pharmaceutical pipeline to advance Personalized Medicine for the improvement of individualized healthcare.

Jean-Pierre Kocher

Jean-Pierre Kocher, Bioinformatics Core Director, Health Sciences Research, Mayo Clinic

Jean-Pierre Kocher, Bioinformatics Core Director, Health Sciences Research, Mayo Clinic

Dr. Kocher joined Mayo Clinic in October 2005 to create and direct the activities of the Bioinformatics Program at the Mayo Clinic. In 2008, he became Chair of the Division of Biomedical Statistics and Informatics that regrouped experts in Biostatistics, Bioinformatics, Medical Informatics and Computer Science. The division develops, maintains, and promotes state of the art analytical and informatics methods and expertise provide high-value collaboration and research services for investigators involved in basic science, translational and clinical research. Prior to joining Mayo Clinic, Dr. Kocher was Director of Computational Chemistry at Camitro Corp., where his responsibilities included the development of computational models to predict ADME properties of drug-like compounds.

Laurence Marton

Laurence Marton, Program Committee Chairman, PMWC

Laurence Marton, Program Committee Chairman, PMWC

Dr. Marton serves as a consultant to industry and to governmental and academic institutions. In recent years he has been a founder, director, CEO, CSO, and CMO of the SLIL Biomedical Corporation, and CSO of both Cellgate and Progen Pharmaceuticals. These companies were, or are, focused on the discovery and development of novel compounds for the treatment of cancer and other serious diseases. Before moving from academia to industry, Dr. Marton was Dean of the University of Wisconsin-Madison Medical School and previously Chaired the Department of Laboratory Medicine at the University of California, San Francisco (UCSF), where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. He remains an Emeritus Professor in the Department of Laboratory Medicine at UCSF. He is a leading expert with extensive experience in the fields of cell growth and drug development. His work is focused on the use of polyamine analogs in treating human diseases related to aberrant cell growth and epigenetics, including cancer and other diseases. Dr. Marton serves as a director on the Boards of the California Heart Center Foundation and Cancer Commons, and as a trustee of the American Association for Cancer Research Foundation. He is on the Board of Directors of TOMA Biosciences, is Chair of the Scientific Advisory Board of PharmaJet, and is on the Advisory Boards of Ruga Corp and Contrast Therapeutics. Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University.

Lawrence Lesko

Lawrence Lesko, Professor, College of Pharmaceutics, University of Florida

Lawrence Lesko, Professor, College of Pharmaceutics, University of Florida

Dr. Lesko is a Professor of Pharmaceutics at the Univeristy of Florida. He was previously Director of the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research at the FDA. He was Chair of the FDA Pharmacogenomics Working Group and the Clinical Pharmacology Section of the Medical Policy Coordinating Committee in CDER. He has received the ASCPT Rawls-Palmer Progess in Medicine Award (2007) and the Gary Neil Prize for Innovation in Drug Development in 2010, was honored with the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Award for Clinical Service (2007), and was awarded the Nathaniel T Kwit Memorial Distinguished Service Award from ACCP in September 2007.

Peter Yu

Peter Yu, Director of Cancer Research, Palo Alto Medical Foundation

Peter Yu, Director of Cancer Research, Palo Alto Medical Foundation

Dr. Peter Paul Yu is in clinical practice and is also Director of Cancer Research at the Palo Alto Medical Foundation (PAMF), a multi specialty medical group serving the San Francisco Bay area. Dr. Yu graduated from the combined undergraduate and medical school Program in Medicine at Brown University. Dr. Yu has served as co-chair of the Commission for Certification of Health Information Technology (CCHIT) Oncology work group, co-chair of the AMA-RAND Clinical Decision Support Oncology work group under contract to the Office of the National Coordinator for Health Information Technology and as co-chair of the ASCO-NCI CORE project.

Ralph Snyderman

Ralph Snyderman, Chancellor Emeritus, Duke University

Ralph Snyderman, Chancellor Emeritus, Duke University

Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He is currently a visiting professor in the Global Health Science Center of the University of California at San Francisco. From 1989 to July 2004, he served as Chancellor for Health Affairs and Dean of the School of Medicine. During this period, he oversaw the development of the Duke University Health System, one of the few fully integrated academic health systems in the country, and served as its Chief Executive Officer. The health system provides not only leading edge care, but is also developing tomorrow's models of health care delivery. Dr. Snyderman has been a leading proponent of a new approach to health called "Prospective Care." This model envisions each individual receiving a personalized health plan based on their own risks and needs. This will give people far more control of and responsibility for their own health as well as opportunities to improve it. Prospective Care combines the best in science and technology with humanistic medical practice and relies on integrative medicine to do this. Dr. Snyderman is the recipient of numerous honors, including the highest awards in the field of inflammation research, the Lifetime Achievement Award from the Arthritis Foundation and the first Bravewell Leadership Award for outstanding achievements in the field of integrative medicine. He is a member of the Institute of Medicine and American Academy of Arts & Sciences, past chair of the Association of American Medical Colleges and immediate past president of the American Association of Physicians.

Russ Altman

Russ Altman, Chairman, Dept. of Bioengineering, Stanford University

Russ Altman, Chairman, Dept. of Bioengineering, Stanford University

Russ Biagio Altman is professor of bioengineering, genetics, & medicine (and of computer science by courtesy) and chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing technology to basic molecular biological problems of relevance to medicine. He is currently developing techniques for collaborative scientific computation over the Internet, including novel user interfaces to biological data, particularly for pharmacogenomics (e.g. http://www.pharmgkb.org/). Other work focuses on the analysis of functional microenvironments within macromolecules and the application of algorithms for determining the structure, dynamics and function of biological macromolecules (e.g. http://simbios.stanford.edu/). Dr. Altman holds an M.D. from Stanford Medical School, a Ph.D. in medical information sciences from Stanford, and an A.B. from Harvard College. He has been the recipient of the U.S. Presidential Early Career Award for Scientists and Engineers, a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians and the American College of Medical Informatics. He is a past-president and founding board member of the International Society for Computational Biology, an organizer of the annual Pacific Symposium on Biocomputing. He leads one of seven NIH-supported National Centers for Biomedical Computation, focusing on physics-based simulation of biological structures (http://simbios.stanford.edu/). He won the Stanford Medical School graduate teaching award in 2000.

Scott Patterson

Scott Patterson, Executive Director, Medical Sciences Amgen Inc.

Scott Patterson, Executive Director, Medical Sciences Amgen Inc.

Dr. Patterson is an Executive Director in the Medical Sciences function at Amgen leading the In Vitro Diagnostic Group which is responsible for the identification, implementation and management of diagnostic partnering strategies for all Amgen therapeutics. He was previously VP of Proteomics at the Celera Genomics Group and the Chief Scientific Officer of Farmal Biomedicines, LLC. While at Celera, he established the company's initial foray into identification of cell surface targets for oncology, a number of which have been licensed. He was at Amgen from 1993–2000 ultimately leading the Department of Biochemistry and Genetics. His academic career began at The University of Queensland where he held research positions of increasing responsibility over a period of 11 years, culminating in that of Senior Research Officer.

Sheila Walcoff

Sheila Walcoff, Founding Principal, Goldbug Strategies LLC

Sheila Walcoff, Founding Principal, Goldbug Strategies LLC

Sheila D. Walcoff is a partner in the Washington DC office of the law firm of McDermott Will & Emery LLP and a member of the Firm’s Health Industry Advisory Group and co-leads the Life Sciences/Medical Products Government Strategies Team. Previously, Ms. Walcoff served as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS), Associate Commissioner for External Affairs at the Food and Drug Administration (FDA) and the health policy team leader/senior health policy advisor to a 2008 presidential campaign. She also has significant legislative strategy and advocacy experience and served as the majority counsel to the U.S. House of Representatives Armed Services Committee. Her ongoing pro bono work includes legislative and policy counsel to a national eating disorder association. Ms. Walcoff serves on the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS), the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation (CBI) Strategy and Policy Council, and the Board of the Friends of the National Zoo (FONZ).

Track 3 Screening Committee

Doug Fisher

Doug Fisher, Interwest

Doug Fisher, Interwest

Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical and diagnostics investments. He is a board member of Cardiac Dimensions, Gynesonics, Sera Prognostics and USDS. Dr. Fisher also is actively involved in InterWest's investments in Integrated Diagnostics and Invuity. Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in three new disease areas for Remicade. Dr. Fisher received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.

Mike Hoerres

Mike Hoerres, MS, Principal, Geisinger Ventures

Mike Hoerres, MS, Principal, Geisinger Ventures

A Principal in Geisinger Ventures, Mike Hoerres is responsible for working with colleagues in Geisinger research and the Geisinger Clinic to commercialize new discoveries in the life sciences, genomics and proteomic research areas that will ultimately lead to improvements in patient care. A seasoned professional with extensive entrepreneurial and operations experience in life science and biopharmaceutical companies, Mr. Hoerres brings to the position exceptional industry and scientific knowledge. He is skilled at strategic counsel as well as the hands-on support to foster growth in new projects. Prior to joining Geisinger, Hoerres was Vice President of Business Development at Source MDx, where he shepherded the licensing of the Source MDx platform for use in the clinical trial businesses of the nation’s two largest reference laboratories. He also developed biomarker and companion diagnostic collaborative agreements, including licensing rights to companion diagnostics and stand-alone diagnostics, based on collaborative research plans. Prior to that, he served as Clinical Market Development Manager at Affymetrix and Director of Business Development at Incyte Genomics. Hoerres holds a BS in biochemistry of University of Wisconsin – Milwaukee and a MS in molecular immunology from San Diego State University.

Myla Lai-Goldman

Myla Lai-Goldman, MD Managing Partner Personalized Science, LLC

Myla Lai-Goldman, MD Managing Partner Personalized Science, LLC

In 2009, Dr. Lai-Goldman founded and became the managing partner of Personalized Science, LLC, a consulting company whose mission is to assist its customers achieve successful adoption of innovative diagnostics with actionable results for patient’s unmet medical needs. In 2011, Dr Lai-Goldman founded and became CEO of GeneCentric Diagnostics, Inc., focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions. Additionally, Dr. Lai-Goldman became a Venture Partner with Hatteras Venture Partners, Inc, a venture capital firmed based in Research Triangle Park, NC. Until her retirement on December 31, 2008, Myla P. Lai-Goldman, M.D. was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), From 1998 until April 2008, Dr. Lai-Goldman also served as Chief Scientific Officer of the company. Dr. Lai-Goldman joined the Company in 1990. Dr. Lai-Goldman earned an MD from the College of Physicians and Surgeons at Columbia University in New York. She is board-certified in anatomic and clinical pathology.

Stacy Feld

Stacy Feld, Partner, Physic Ventures

Stacy Feld, Partner, Physic Ventures

Stacy Feld, J.D., is a Partner at Physic Ventures. Stacy focuses on personalized health solutions to improve and transform care for the health consumer. Specifically, Stacy is interested in life science opportunities offering more precise prevention, diagnosis, and treatment of chronic disease. She is on the board of T2 Biosystems and an observer on the boards of On-Q-ity and Own.

    This entire site is licensed under Creative Commons Attribution-NoDerivs.   |   © Copyright PMWC International